 hold pt in-lin result guidanc expect price pressur return
product cycl wane reduc pt analyst nehal chokshi full summari
seanergi maritim hold corp ship buy pt better scrubber strategi charter pay capit
 buy pt investor day review uniqu franchis continu deliv superior
soligenix inc sngx buy pt public innat defens regul technolog pivot trial on-going
new beverag corp hold announc acquisit multi-level market compani morinda hold
maintain hold await audit financi analyst anthoni vendetti full summari
corpor event call maxim salesperson inform
women health dinner agrx bioscienc dare vivev medic inc vive
kol host palomequ mccarthi vendetti thu dec
inc cover klee ndr boston senior director financ suzann lynn director
financ lynn um mon dec
maxim group first annual tmt confer brq ctrl cybi st hyre
mcld smci vuzi wisa host chokshi klee tue dec
turtl beach corpor hear cover chokshi ndr san francisco san jose ceo juergen stark
pitney bow inc cover klee ndr milwauke madison cfo stan sutula tue dec
pitney bow inc cover klee ndr chicago cfo stan sutula vice-president investor relat adam david
investor relat june vecellio wed dec
investor day review uniqu franchis continu
host investor day decemb view deliv
import theme make uniqu therefor less suscept
damag competit
expect manag highlight uniqu non-
replic enjoy command market share among
early-stag technolog life scienc compani power
relationship ventur capit vc backer compani
offer compani includ proprietari
advic employe access network peer industri
expert develop global infrastructur servic
relev type compani grow therebi enabl
keep client lifespan pend acquisit
leerink partner add capit market servic debt equiti
convert advisori servic gener signific
synergi full-servic commerci invest bank product
offer help attract client help captur greater share
client total bank need see detail
accord manag uniqu franchis gener core
ep growth increas rate environ
flat-rat environ roe normalized-r
environ fed fund rate lower-r
environ differ scenario relat strong asset sensit
maintain ep estim price target
buy rate lower ep estim
mainli due lower gains/loss invest secur equiti
warrant page earn model stock current trade
ep estim price target equat price-to-earnings
multipl modest premium best-in-class smid-cap
bank believ premium justifi uniqu
remain top pick among smid-cap bank long term
short term expect share rebound over-sold level
result part over-react preliminari guidanc see
note link expens growth investor day manag
note near-term expens growth devot process
improv help reduc growth fte far biggest
part expens growth therebi help reduc long-term expens
one advantag investor day exposur depth manag addit
ceo greg becker presid mike descheneaux cfo beck chief credit
offic marc cadieux regular quarterli earn call
present includ mani senior execut impress
view also appar us pride excit
work especi enlighten us lot inform
follow necessarili order import includ point consid
competit stronger ever win-rat remain steadi busi
want win tend better compani mani
sinc incept indic one assum better
compani make public market percentag ipo involv client
nearli doubl current five eight year ago
healthcar life scienc client posit leerink
acquisit accord manag one factor convinc
leerink appropri acquisit candid leerink organ
exactli way regard healthcar life scienc subsector
overlap area expertis client coverag also ident
ceo greg becker said fit within platform
recent senior hire includ chief product offic chief deposit offic
head privat bank wealth advisori latter area major opportun
think citi nation bank view accord becker compani
scratch surfac
though market share among early-stag technolog
life scienc compani still mani growth opportun exampl
penetr early-stag client credit card
market share among european ventur capital-back compani
loan early-stag compani account loan
import loan earli stage compani account far highest
percentag credit losses/net charge-off howev earli stage compani
extrem import gener relationship last
throughout compani lifetim also account on-balance-
sheet deposit off-balance-sheet client fund
capit call line privat equity/ventur capit compani account
loan import credit loss capit
call line year manag soft target rang
capit call line rel total loan one reason manag believ
prudent achiev goal mani pe/vc fund never lightli
use line start competit reason order boost
return word size market increas
lot question air pocket possibl
result distribut lp pe/vc fund larg gain gener
distribut like neg impact on-balance-sheet deposit
though total client fund size secur portfolio therebi
net interest incom howev fed fund rate hike month would off-set
accord manag everi hike increas net interest incom
million view rel non-ev
also question chang deposit mix ask manag
confid dda balanc could possibl decreas current total
deposit accord manag repres
level so-cal oper account dda account
oper fund client flow account backbon
relationship busi model
top pick among smid-cap bank long term reiter buy rate
next year expect appreci stock price price target
remain top pick among smid-cap bank long term due
uniqu non-replic franchis growth implic franchis
click full note
in-lin result guidanc expect price pressur
return product cycl wane reduc pt
octob quarter oper result consensu larg due
guidanc reflect server margin remain upward trajectori
product cycl wane expect margin pressur return
year-end analysi indic embed full-year
maintain hold rate slightli reduc price target
one-year delay match normal
octob quarter oper result consensu larg due
improv server margin octob quarter revenu y/i
constant currenc cc basi consensu ep
midpoint guidanc also consensu howev note oper
profit consensu estim ep
impli lower consensu interest expens tax share count repres
ep beat segment perspect hybrid revenu
y/i y/i cc consensu hybrid om
consensu drive oper ep beat note hybrid
om y/i slight deceler jul om improv
despit lower margin product grow y/i lower margin pointnext
servic declin y/i result exit advisori profession servic
low margin countri interpret manag commentari lead us
believ improv hybrid om result on-going mix shift higher
margin product high-perform comput hyperconverg infrastructur
becom busi vs total server revenu maintain
price power result server differenti larg util
decad old root trust technolog protect server bio malici
chang benefit dram nand flash price continu declin
jan guidanc reflect server margin remain upward trajectori
product cycl wane expect margin pressur return
year-end analysi indic embed full-year guidanc
januari quarter ep guidanc bracket consensu
given higher interest expens guidanc due rise interest rate
aggress buyback drain cash balanc
vs triangul guidanc emb hybrid om continu
increas y/i howev also triangul full-year non-gaap ep
guidanc impli overal om pressur back half
year possibl guidanc reflect normal conservat concern
conservat warrant given decades-old technolog unusu
margin come pressur server product cycl wane end
server toward end second year typic year cycl
maintain hold rate slightli reduc price target
one-year delay match normal cycl forward
price target basi manag guid delta
normal actual shrink
also shift price target basi ev/ni ev/fcf
discount back one year price target base
multipl estim less non-accret
acquisit plu oper net cash maintain hold rate
click full note
public innat defens regul technolog
pivot trial on-going oral mucos
soligenx announc public scientif review articl discuss
clinic applic innat defens regul technolog includ
dusquetid articl entitl target innat immun treat
diseas potenti applic publish journal
dusquetid current on-going phase trial treatment
oral mucos due chemoradi therapi crt oral mucos
result inflamm crt sever patient stop
treatment pain eat studi
median durat oral mucos reduc
receiv aggress crt phase data expect
target innat immun immuno oncolog advanc across biotechnolog
space focu rise valuat driven approach
howev key compon immun respons cancer infect
inflamm innat immun respons first line defens innat
immun system first line defens infect trigger inflamm
bacteria remov pathogen damag associ molecular pattern
detect pamp damp well start anti-canc respons
long cell come pictur trigger innat defens macrophag
neutrophil monocyt induc output cytokin activ immun
mediat natur killer cell antigen present cell dendrit cell
turn bridg orchestr cell-medi cell humor cell
dusquetid innat defens regul idr target highli
conserv intermedi protein signal network innat immun respons
target dusquetid reduc inflamm time actual
increas protect bacteria also direct anti-canc effect
express certain cancer particularli use indic like
prevent oral mucos associ high-dos chemotherapi radiat
head neck cancer allevi inflamm caus patient abl
eat even stop therapi pain prevent infect even contribut
kill cancer oral mucos remain area high unmet need
dom-inn studi demonstr posit safeti
profil healthi subject studi patient undergo
chemoradi therapi crt reduc median durat oral mucos
patient receiv aggress crt patient
experienc reduc bacteri infect increas incid complet
respons tumor maintain follow-up
trial multicent random double-blind placebo-control studi
evalu dusquetid oral mucos patient head neck
cancer receiv chemoradi therapi crt primari endpoint studi
median durat sever oral mucos assess oral examin
treatment visit six week follow complet crt
receiv track design fda interim data expect
top-line note posit phase could also suffici approv
ema
click full note
sophiri phase studi topsalysin local prostat cancer
approach next key data point effect second administr
expect next week
recal studi alreadi demonstr patient respons rate
 partial clinic includ six complet ablat
like suffici combin prior data move program howev
second administr patient multipl implic
posit catalyst sph share
safeti lack immunogen repeat dose
efficaci would suggest partial respons could potenti
convert clinic complet ablat get patient back
extend time androgen depriv cryotherapi high
frequenc ultrasound prostatectomi
data support
review prior data singl admin design possibl outcom
second admin page thu far even singl administr
data suggest topsalysin may significantli extend time radic
therapi multipl unwant side effect posit topsalysin
potenti disrupt altern earli stage pc space
topsalysin prostat cancer pc treatment paradigm consid
pc much focu turn metastat castrat resist pc mcrpc
xtandi zytiga led acquisit cougar biotechnolog
 nr mediv nr drug
start push earlier line therapi xtandi erleada
approv non-mcrpc earlier stage diseas pc start
local diseas risk-stratifi base gleason score low high
risk metastasi case per year low risk gleason score
latter high risk gleason need
cryotherapi hifu prostatectomi xtandi/erleada/zytiga potenti
intermedi risk gleason topsalysin fit men like requir one
aforement therapi may reluct undergo side
effect sexual dysfunct incontin cryotherapi hifu costli
doc patient requir day cather sexual dysfunct high risk
prostatectomi come essenti side effect note
topsalysin could altern cryo hifu better option
prostatectomi topsalysin also use ultrasound guidanc inject
imag use prostat biopsi doc familiar administr topsalysin
minut side effect patient goe home
overal topsalysin significantli delay time approach may
attract option patient doc payer addit delay time
therapi includ drug like xtandi topsalysin could disrupt pc space
potenti attract partner space look expand earli stage diseas
view singl administr data demonstr six complet ablat six-
month follow long last given slow grow natur earli pc
could significantli longer patient follow longer term second
administr data expect could translat even longer delay
therapi
click full note
